Table 4 Comparison of clinical characteristics between the MPR group and the non-MPR group
Non-MPR | MPR | P | |
|---|---|---|---|
Patients | 16 (44.4%) | 20 (55.6%) | |
Age | 66.5 (62.0–68.0) | 60.5 (54.5–67.8) | 0.147 |
Sex | |||
Male | 12 (75.0%) | 16 (80.0%) | |
Female | 4 (25.0%) | 4 (20.0%) | 1.000 |
Smoking history | |||
No | 6 (37.5%) | 6 (30.0%) | |
Yes | 10 (62.5%) | 14 (70.0%) | 0.729 |
Treatment cycles | |||
2 | 8 (50.0%) | 10 (50.0%) | |
3 | 6 (37.5%) | 4 (20.0%) | |
4 | 2 (12.5%) | 6 (30.0%) | 0.321 |
Adverse effect | |||
No | 0 | 2 (10.0%) | |
Grades 1–2 | 13 (81.2%) | 12 (60.0%) | |
Grades 3–5 | 3 (18.8%) | 6 (30.0%) | 0.184 |
Pre-treatment PD-L1 expression | |||
Negative | 6 (37.5%) | 2 (10.0%) | |
Positive | 2 (12.5%) | 8 (40.0%) | |
Unknown | 8 (50.0%) | 6 (30.0%) | 0.054 |
Pathology | |||
Squamous cell carcinoma | 8 (50.0%) | 11 (55.0%) | |
Adenocarcinoma | 5 (31.3%) | 4 (20.0%) | |
Non-small-cell lung cancer | 3 (18.8%) | 5 (25.0%) | 0.724 |
Clinical stage | |||
IIB | 1 (6.3%) | 3 (15.0%) | |
IIIA | 13 (81.2%) | 7 (35.0%) | |
IIIB | 2 (12.5%) | 7 (35.0%) | |
IIIC | 0 | 3 (15.0%) | 0.023 |
Radiological response | |||
CR | 0 | 8 (40.0%) | |
PR | 12 (75.0%) | 12 (60.0%) | |
SD | 4 (25.0%) | 0 | <0.001 |